---
figid: PMC4164812__zlj9991044920001
figlink: /pmc/articles/PMC4164812/figure/F1/
number: Fig 1
caption: Effects of BRAF inhibitors on melanoma and immune cells. Melanoma tumor cells
  with a BRAFV600E mutation experience a decrease in oncogenic mitogen-activated protein
  kinase (MAPK) pathway signaling when treated with a BRAF inhibitor, evidenced by
  phosphorylation of ERK (pERK). (A) In lymphocytes, the exposure to a BRAF inhibitor
  instead leads to a paradoxical activation of the MAPK pathway and increased phosphorylated
  ERK (pERK). (B) BRAF inhibitor therapy in melanoma cells has been reported to increase
  melanoma antigen expression and T-cell recognition directly or indirectly. (C) Chronic
  exposure to BRAF inhibitors has been shown to upregulate the surface expression
  of the immune checkpoint ligand (PD-L1) of programmed death receptor-1 (PD-1). (D)
  The tumor microenvironment (macrophages, tumor-associated fibroblasts [TAFs]) can
  be modulated by BRAF inhibitors to enhance the immune response. IL, interleukin;
  PD-1, programmed death receptor-1; MDSC, myeloid-derived suppressor cell; MEKi,
  MEK inhibitor; TCR, T-cell receptor; TIL, tumor-infiltrating lymphocyte; TNF-α,
  tumor necrosis factor alpha; Tyr, tyrosinase; VEGF, vascular endothelial growth
  factor.
pmcid: PMC4164812
papertitle: 'Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma:
  Promise and Challenges.'
reftext: Siwen Hu-Lieskovan, et al. J Clin Oncol. 2014 Jul 20;32(21):2248-2254.
pmc_ranked_result_index: '58371'
pathway_score: 0.9564248
filename: zlj9991044920001.jpg
figtitle: BRAF inhibitors on melanoma and immune cells
year: '2014'
organisms: Homo sapiens
ndex: 20ecf3d5-dee8-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4164812__zlj9991044920001.html
  '@type': Dataset
  description: Effects of BRAF inhibitors on melanoma and immune cells. Melanoma tumor
    cells with a BRAFV600E mutation experience a decrease in oncogenic mitogen-activated
    protein kinase (MAPK) pathway signaling when treated with a BRAF inhibitor, evidenced
    by phosphorylation of ERK (pERK). (A) In lymphocytes, the exposure to a BRAF inhibitor
    instead leads to a paradoxical activation of the MAPK pathway and increased phosphorylated
    ERK (pERK). (B) BRAF inhibitor therapy in melanoma cells has been reported to
    increase melanoma antigen expression and T-cell recognition directly or indirectly.
    (C) Chronic exposure to BRAF inhibitors has been shown to upregulate the surface
    expression of the immune checkpoint ligand (PD-L1) of programmed death receptor-1
    (PD-1). (D) The tumor microenvironment (macrophages, tumor-associated fibroblasts
    [TAFs]) can be modulated by BRAF inhibitors to enhance the immune response. IL,
    interleukin; PD-1, programmed death receptor-1; MDSC, myeloid-derived suppressor
    cell; MEKi, MEK inhibitor; TCR, T-cell receptor; TIL, tumor-infiltrating lymphocyte;
    TNF-α, tumor necrosis factor alpha; Tyr, tyrosinase; VEGF, vascular endothelial
    growth factor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL1B
  - IL1A
  - MAPK3
  - PMEL
  - MAP2K2
  - CCL2
  - TRD
  - IL10
  - MAPK1
  - TNF
  - TRG
  - VEGFD
  - TRB
  - VEGFB
  - MITF
  - TRA
  - MAP2K1
  - BRAF
  - EIF2AK3
  - PDCD1
  - VEGFC
  - VEGFA
  - PGF
  - TYR
  - IL33
  - CD274
  - IL6
genes:
- word: IL-1
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
- word: IL-1
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1A
  entrez: '3552'
- word: ↑ÞERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: gp100
  symbol: gp100
  source: hgnc_alias_symbol
  hgnc_symbol: PMEL
  entrez: '6490'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: CCL2
  symbol: CCL2
  source: hgnc_symbol
  hgnc_symbol: CCL2
  entrez: '6347'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: IL-10,
  symbol: IL-10
  source: hgnc_alias_symbol
  hgnc_symbol: IL10
  entrez: '3586'
- word: ↑ÞERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: TNF
  symbol: TNF
  source: hgnc_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: MITF
  symbol: MITF
  source: hgnc_symbol
  hgnc_symbol: MITF
  entrez: '4286'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PERK
  symbol: PERK
  source: hgnc_alias_symbol
  hgnc_symbol: EIF2AK3
  entrez: '9451'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: Tyr
  symbol: TYR
  source: hgnc_symbol
  hgnc_symbol: TYR
  entrez: '7299'
- word: IL-1,33
  symbol: IL33
  source: hgnc_symbol
  hgnc_symbol: IL33
  entrez: '90865'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: TNF-a
  symbol: TNF-alpha
  source: hgnc_alias_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: IL-6,
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
chemicals: []
diseases: []
---
